Insulet (PODD) Competitors

IDEXX Laboratories (NASDAQ:IDXX) and Insulet (NASDAQ:PODD) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, media sentiment, dividends, risk, analyst recommendations, earnings and valuation.

Do institutionals and insiders believe in IDXX or PODD?

87.8% of IDEXX Laboratories shares are held by institutional investors. 1.0% of IDEXX Laboratories shares are held by insiders. Comparatively, 0.4% of Insulet shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Does the media favor IDXX or PODD?

In the previous week, IDEXX Laboratories had 2 more articles in the media than Insulet. MarketBeat recorded 42 mentions for IDEXX Laboratories and 40 mentions for Insulet. IDEXX Laboratories' average media sentiment score of 1.14 beat Insulet's score of 1.04 indicating that IDEXX Laboratories is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IDEXX Laboratories	29 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Insulet	20 Very Positive mention(s)	6 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has stronger earnings and valuation, IDXX or PODD?

IDEXX Laboratories has higher revenue and earnings than Insulet. IDEXX Laboratories is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEXX Laboratories	$4.04B	12.96	$887.87M	$12.01	54.45
Insulet	$2.36B	9.42	$418.30M	$3.29	95.98

Which has more volatility & risk, IDXX or PODD?

IDEXX Laboratories has a beta of 1.49, indicating that its stock price is 49% more volatile than the S&P 500. Comparatively, Insulet has a beta of 1.35, indicating that its stock price is 35% more volatile than the S&P 500.

Is IDXX or PODD more profitable?

IDEXX Laboratories has a net margin of 24.41% compared to Insulet's net margin of 10.01%. IDEXX Laboratories' return on equity of 64.42% beat Insulet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IDEXX Laboratories	24.41%	64.42%	29.89%
Insulet	10.01%	23.78%	9.30%

Do analysts rate IDXX or PODD?

IDEXX Laboratories currently has a consensus price target of $644.67, indicating a potential downside of 1.42%. Insulet has a consensus price target of $330.71, indicating a potential upside of 4.73%. Given Insulet's stronger consensus rating and higher possible upside, analysts clearly believe Insulet is more favorable than IDEXX Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEXX Laboratories	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.80
Insulet	0 Sell rating(s)	2 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.89

Summary

IDEXX Laboratories beats Insulet on 13 of the 17 factors compared between the two stocks.